NK cells in therapy of cancer.
暂无分享,去创建一个
[1] O. Janssen,et al. Shedding of endogenous MHC class I‐related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17 , 2013, International journal of cancer.
[2] Bin Zhang,et al. Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition , 2013, Clinical Cancer Research.
[3] Bin Zhang,et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). , 2013, Blood.
[4] J. Wagner,et al. Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2 , 2012 .
[5] Jeffrey S. Miller,et al. Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen , 2012, The Journal of Immunology.
[6] L. Weiner,et al. Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production , 2012, Molecular Cancer Therapeutics.
[7] L. Ruggeri,et al. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant , 2012, Current opinion in hematology.
[8] Charles C. Kim,et al. NK Cells and Immune “Memory” , 2011, The Journal of Immunology.
[9] Joseph C. Sun,et al. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection , 2011, The Journal of experimental medicine.
[10] L. Downs,et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.
[11] H. Pircher,et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. , 2010, Blood.
[12] Chap T Le,et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. , 2010, Blood.
[13] D. Raulet,et al. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment , 2010, The Journal of experimental medicine.
[14] B. Lindgren,et al. Allogeneic natural killer cells for refractory lymphoma , 2010, Cancer Immunology, Immunotherapy.
[15] Jeffrey S. Miller,et al. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] D. Kaufman. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. , 2009, Blood.
[17] Lewis L Lanier,et al. Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.
[18] G. Screaton,et al. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity , 2007, European journal of immunology.
[19] Yan Tang,et al. Recombinant Interleukin-2 Significantly Augments Activity of Rituximab in Human Tumor Xenograft Models of B-cell Non-Hodgkin Lymphoma , 2007, Journal of immunotherapy.
[20] P. Parham. Taking license with natural killer cell maturation and repertoire development , 2006, Immunological reviews.
[21] R. Oostendorp,et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. , 2006, Blood.
[22] R. Vance,et al. Self-tolerance of natural killer cells , 2006, Nature Reviews Immunology.
[23] D. Raulet. Missing self recognition and self tolerance of natural killer (NK) cells. , 2006, Seminars in immunology.
[24] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[25] E. Lanino,et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). , 2005, Blood.
[26] Lewis L Lanier,et al. NK cell recognition. , 2005, Annual review of immunology.
[27] L. Moretta,et al. Killer immunoglobulin-like receptors. , 2004, Current opinion in immunology.
[28] D. Vesole,et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial , 2003, Bone Marrow Transplantation.
[29] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[30] Jeffrey S. Miller,et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. , 1999, Experimental hematology.
[31] A. Tosti,et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.
[32] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[33] L. Lanier,et al. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. , 1988, Journal of immunology.
[34] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[35] H. Ljunggren,et al. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.
[36] I. Kimber. Natural killer cells. , 1985, Medical laboratory sciences.
[37] R. Herberman,et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells , 1975, International journal of cancer.
[38] R. Herberman,et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity , 1975, International journal of cancer.